TD Cowen Maintains Buy on Milestone Pharmaceuticals, Lowers Price Target to $5

Benzinga · 3d ago
TD Cowen analyst Ritu Baral maintains Milestone Pharmaceuticals (NASDAQ:MIST) with a Buy and lowers the price target from $8 to $5.